Galapagos achieves clinical Proof-of-Mechanism milestone in GSK alliance
GLPG0778 shows statistically significant and selective effects on biomarkers in healthy volunteers
22-Dec-2011 -
Galapagos NV announced that investigational medicine GLPG0778, which is part of its immuno-inflammatory alliance with GlaxoSmithKline, has shown selective effects on a biomarker in a Phase I Proof-of-Mechanism study in healthy volunteers. The study also provided information on the safety and ...
biomarkers
Galapagos
GlaxoSmithKline
+3